Roger Maxfield, MD
Pulmonary Disease · New York, NYNPI 1073536405
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $191 of the $242 with a category attached, or 78.7%. GSK accounts for 66.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $194 and has fallen 81.0% since, to $37 in 2025. That places this record below the midpoint for pulmonary disease clinicians in NY, where the typical reported total is $756.
Across 6 payments — averaging $40.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$162
- Genentech USA, Inc.$40
- Insmed, Inc.$29
- AstraZeneca$12
Across 2 payments — averaging $9271.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pneumrx, Inc$19K
What the payments were for
- Food & beverage$19179%
- Education$5221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 3 | $162 |
| Genentech USA, Inc. | 1 | $40 |
| Insmed, Inc. | 1 | $29 |
| AstraZeneca | 1 | $12 |
How this compares
$242 in reported general payments places this provider in the 30th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 29 | $364,261 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 153 | $115,979 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 184 | $108,958 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $44,506 |
| XareltoRivaroxaban | 24 | $28,179 |
| Incruse ElliptaUmeclidinium Bromide | 58 | $23,383 |
| Qvar RedihalerBeclomethasone Dipropionate | 57 | $22,609 |
| EliquisApixaban | 30 | $21,793 |
| Spiriva HandihalerTiotropium Bromide | 14 | $15,859 |
| Spiriva RespimatTiotropium Bromide | 27 | $14,296 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $14,054 |
| Arnuity ElliptaFluticasone Furoate | 51 | $11,559 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $8,681 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $6,034 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $4,387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $162 | $304,385530 claims |
| AstraZenecaSymbicort | $12 | $4,38717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.